Predictive Value of Combining Inflammatory Biomarkers and Rapid Decline of FEV₁ for COPD in Chinese Population: A Prospective Cohort Study

References

• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1256–1276. doi:10.1164/ajrccm.163.5.210103911316667
   PubMedGoogle Scholar
• Yao W, Wang C, Zhong N, et al. Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study. Respirology. 2014;19:231–238. doi:10.1111/resp.1221124383720
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-023245604
   PubMed Web of Science ®Google Scholar
• Marc Decramer WJMM. Chronic obstructive pulmonary disease. Lancet. 2012;1341–1351. doi:10.1016/S0140-6736(11)60968-9
   Web of Science ®Google Scholar
• Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med. 2013;1:43–50. doi:10.1016/S2213-2600(12)70044-924321803
   PubMed Web of Science ®Google Scholar
• Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China. Am J Respir Crit Care Med. 2007;176:753–760. doi:10.1164/rccm.200612-1749OC17575095
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L. Prevalence and risk factors of chronic obstructive pulmonary disease in China (The China Pulmonary Health [CPH] study): a national cross-sectional study. The Lancet. 2018;391:1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276.
   Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1.
   Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653. doi:10.1056/NEJMoa03215815215480
   PubMed Web of Science ®Google Scholar
• Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31:1334–1356. doi:10.1183/09031936.0001890818515558
   PubMed Web of Science ®Google Scholar
• Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97:1299–1302. doi:10.1016/j.rmed.2003.07.00814682411
   PubMed Web of Science ®Google Scholar
• Kolsum U, Roy K, Starkey C, et al. The repeatability of interleukin-6, tumor necrosis factor- α, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis. 2009;4:149–156. doi:10.2147/COPD.S501819436686
   PubMedGoogle Scholar
• Bhowmik A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120. doi:10.1136/thorax.55.2.11410639527
   PubMed Web of Science ®Google Scholar
• Horváth I, Hunt J, Barnes PJ. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26:523–548. doi:10.1183/09031936.05.0002970516135737
   PubMed Web of Science ®Google Scholar
• Kullmann T, Barta I, Lazar Z, et al. Exhaled breath condensate pH standardised for CO2 partial pressure. Eur Respir J. 2007;29:496–501. doi:10.1183/09031936.0008400617079255
   PubMed Web of Science ®Google Scholar
• HUNT JF, Fang K, Malik R. Endogenous airway acidification: implications for asthma pathology. Am J Resp Crit Care Med. 2000;161:694–699. doi:10.1164/ajrccm.161.3.991100510712309
   PubMed Web of Science ®Google Scholar
• Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P, Loukides S. pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit Care Med. 2002;165:1364–1370. doi:10.1164/rccm.200111-068OC12016097
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi:10.1016/S0092-8674(04)00045-514744438
   PubMed Web of Science ®Google Scholar
• Liu X, Qu J, Xue W, et al. Bioinformatics-based identification of potential microRNA biomarkers in frequent and non-frequent exacerbators of COPD. Int J Chron Obstructive Pulm Dis. 2018;13:1217–1228.
   Web of Science ®Google Scholar
• Duan Y, Zhou M, Xiao J, et al. Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease. Int J Mol Med. 2016;38:1450–1462. doi:10.3892/ijmm.2016.276128025995
   PubMed Web of Science ®Google Scholar
• Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest. 2014;145.
   Web of Science ®Google Scholar
• Wang ML, Avashia BH, Petsonk EL. Interpreting periodic lung function tests in individuals: the relationship between 1- to 5-year and long-term FEV1 changes. Chest. 2006;130.
   Web of Science ®Google Scholar
• Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004;1.16997733
   PubMedGoogle Scholar
• Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–750. doi:10.1016/S0140-6736(07)61377-417765523
   PubMed Web of Science ®Google Scholar
• Menezes AM, Perez-Padilla R, Jardim JR, et al.; PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet (London, England). 2005:366.
   Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med. 2002;166.12119228
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;14:614–615.
   Google Scholar
• Ramírez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med. 2014;190:996–1002. doi:10.1164/rccm.201404-0720OC25172140
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (London, England). 1999;353.
   Google Scholar
• Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340.9929523
   PubMed Web of Science ®Google Scholar
• Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69:336–349. doi:10.1111/ijcp.2015.69.issue-325363328
   PubMed Web of Science ®Google Scholar
• Peabody JW, Schau B, Lopez-Vidriero M, Vestbo J, Wade S, Iqbal A. COPD: a prevalence estimation model. Respirology. 2005;10.
   Web of Science ®Google Scholar
• Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS ONE. 2011;6.
   Web of Science ®Google Scholar
• McLean S, Barbour V, Wild S, Simpson C, Sheikh A. Models for estimating projections for disease prevalence and burden: a systematic review focusing on chronic obstructive pulmonary disease. J Health Serv Res Policy. 2015;20:246–253. doi:10.1177/135581961557923225836652
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The Biology of Interleukin-6. Blood. 1989;74:1–10. doi:10.1182/blood.V74.1.1.12473791
   PubMed Web of Science ®Google Scholar
• Yasuda N, Gotoh K, Minatoguchi S, et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med. 1998;92:993–999. doi:10.1016/S0954-6111(98)90343-29893764
   PubMed Web of Science ®Google Scholar
• Broekhuizen R, Wouters EF, Creutzberg EC, et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61.16254057
   PubMed Web of Science ®Google Scholar
• Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175.
   Web of Science ®Google Scholar
• Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J. 2007;16:236–240. doi:10.3132/pcrj.2007.0004717665081
   PubMedGoogle Scholar
• Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115.12679039
   PubMed Web of Science ®Google Scholar
• Fujita Y, Araya J, Ito S, et al. Suppression of autophagy by extracellular vesicles promotes myofibroblast differentiation in COPD pathogenesis. J Extracell Vesicles. 2015;4:28388. doi:10.3402/jev.v4.2838826563733
   PubMed Web of Science ®Google Scholar
• Osei ET, Florez-Sampedro L, Tasena H, et al. miR-146a plays an essential role in the aberrant epithelial-fibroblast crosstalk in COPD. Eur Respir J. 2017;49:1602538. doi:10.1183/13993003.02538-201628546273
   PubMedGoogle Scholar
• Akbas F, Coskunpinar E, Aynacı E, Müsteri Oltulu Y, Yildiz P. Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Exp Lung Res. 2012;38:286–294. doi:10.3109/01902148.2012.68908822686440
   PubMed Web of Science ®Google Scholar
• Xie L, Wu M, Lin H, et al. An increased ratio of serum miR-21 to miR-181a levels is associated with the early pathogenic process of chronic obstructive pulmonary disease in asymptomatic heavy smokers. Mol Biosyst. 2014;10:1072–1081. doi:10.1039/C3MB70564A24556821
   PubMed Web of Science ®Google Scholar